XW0331BIntroduction of Anitocabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 11
- Billable / Specific Code
- New for FY 2027
XW0331B is a billable ICD-10-PCS procedure code for Introduction of Anitocabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 11. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 018. The root operation Introduction involves putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products.
Code Identity
PCS Table Breakdown
Each ICD-10-PCS code is built from seven characters, each an axis of the procedure. Hover or tap the icons for the official CMS definitions.
| Position | Designation | Value | Meaning |
|---|---|---|---|
| 1 | Section | X | New Technology |
| 2 | Body System | W | Anatomical Regions |
| 3 | Operation | 0 | Introduction |
| 4 | BodyPart | 3 | Peripheral Vein |
| 5 | Approach | 3 | Percutaneous |
| 6 | Device/Substance/Technology | 1 | Anitocabtagene Autoleucel Immunotherapy |
| 7 | Qualifier | B | New Technology Group 11 |
In the ICD-10-PCS Alphabetic Index
These FY 2027 ICD-10-PCS Alphabetic Index entries lead to this code:
Code History
- XW033C7 — Introduce Autolog CAR T in Periph Vein, Perc, New Tech 7
Similar Procedure Codes
Questions About XW0331B
Is XW0331B a billable code?
Yes. This is a complete seven-character ICD-10-PCS code, specific enough to report Introduction of Anitocabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 11 on inpatient claims from October 1, 2026 through September 30, 2027.
What do the characters in XW0331B mean?
The code breaks down character by character: the 1st character X is the Section (New Technology); the 2nd character W is the Body System (Anatomical Regions); the 3rd character 0 is the Operation (Introduction); the 4th character 3 is the BodyPart (Peripheral Vein); the 5th character 3 is the Approach (Percutaneous); the 6th character 1 is the Device/Substance/Technology (Anitocabtagene Autoleucel Immunotherapy); the 7th character B is the Qualifier (New Technology Group 11).
What MS-DRG does XW0331B group to?
On an inpatient stay, Introduction of Anitocabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 11 maps to MS-DRG 018 (chimeric Antigen Receptor (CAR) T-Cell and Other Immunotherapies). The MS-DRG sets the fixed Medicare payment for the stay.
